FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:753-757 August 25, 2005 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In February 2003, after more than a decade of work, a team of scientists representing the biotechnology company VaxGen announced the results of the first phase 3 trial to test the efficacy of a vaccine against the human immunodeficiency virus (HIV). Despite the highest of hopes, their product, AIDSVax — which contains a synthetic monomeric glycoprotein based on glycoprotein 120 (GP120), the CD4-binding site on the outer coat, or envelope, of the virus — did not prevent HIV infection in the study cohort as a whole. It was a frustrating setback for HIV-vaccine research, a field that has endured a . . . [Full Text of this Article]

Source Information

Dr. Markel is a professor of the history of medicine and a professor of pediatrics and communicable diseases at the University of Michigan Medical School, Ann Arbor, where he directs the Center for the History of Medicine.

This article has been cited by other articles:

• Tonks, A. (2007). Quest for the AIDS vaccine. BMJ 334: 1346-1348 [Full Text]